Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center
Status: Enrolling
Updated:  12/27/2017
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center
Status: Enrolling
Updated: 12/27/2017
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders
Status: Enrolling
Updated:  12/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders
Status: Enrolling
Updated: 12/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
New York, NY
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Canton, OH
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
mi
from
Adelaide,
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
mi
from
Adelaide,
Click here to add this to my saved trials
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Cleveland Clinic, The
mi
from
Cleveland, OH
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Cleveland Clinic, The
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Utah
mi
from
Salt Lake City, UT
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
A Two Step Approach To Non-Myeloablative Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Status: Enrolling
Updated:  1/3/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
A Two Step Approach To Non-Myeloablative Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Status: Enrolling
Updated: 1/3/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Phoenix Children's Hospital
mi
from
Phoenix, AZ
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Jonathan Jaques Children'S Cancer Center
mi
from
Long Beach, CA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Jonathan Jaques Children'S Cancer Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Orange County
mi
from
Orange, CA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children'S Hospital
mi
from
Aurora, CO
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children'S Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Chicago
mi
from
Chicago, IL
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Dana Faber Cancer Institute
mi
from
Boston, MA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Oregon Health and Science University
mi
from
Portland, OR
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Texas Children'S Cancer Center
mi
from
Houston, TX
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Texas Children'S Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Seattle Children's
mi
from
Seattle, WA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Seattle Children's
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Local Institution
mi
from
Bunos Aires,
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Local Institution
mi
from
Bunos Aires,
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Stephen D. Hassenfeld Children'S Center
mi
from
New York, NY
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Stephen D. Hassenfeld Children'S Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase I Study of Lenalidomide in Patients With Acute Leukemia
Phase I Trial of High Dose Lenalidomide in Patients With Refractory/Relapsed Acute Leukemia as a Bridge to Bone Marrow Transplant
Status: Enrolling
Updated:  1/5/2018
University of California Comprehensive Cancer Center
mi
from
Sacramento, CA
Phase I Study of Lenalidomide in Patients With Acute Leukemia
Phase I Trial of High Dose Lenalidomide in Patients With Refractory/Relapsed Acute Leukemia as a Bridge to Bone Marrow Transplant
Status: Enrolling
Updated: 1/5/2018
University of California Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Status: Enrolling
Updated:  1/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Status: Enrolling
Updated: 1/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated:  1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated: 1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol
Status: Enrolling
Updated:  1/8/2018
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol
Status: Enrolling
Updated: 1/8/2018
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS
Status: Enrolling
Updated:  1/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS
Status: Enrolling
Updated: 1/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated:  1/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated: 1/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated:  1/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated: 1/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  1/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 1/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials